Akron Biotechnology, which develops and manufactures cGMP-compliant cytokines and other ancillary materials to enable cell and gene therapy development and commercialization, is expanding to a second manufacturing facility in the U.S. Akron Biotech has acquired a state-of-the-art 60,000-square-foot biologics manufacturing site in Sarasota, FL, bolstering the company’s U.S. capacity and strengthening its position as an ancillary materials supplier. The site will be operational later this year.   ...